MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of...
MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of...
MBX生物科學公司宣佈其1期單次和多次遞增劑量試驗中最後一名受試者的最後一次訪問已完成，該試驗針對的是公司的長效胰高血糖素樣肽1受體拮抗劑MBX 1416，該藥物正在開發用於治療...
MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of Post-Bariatric Hypoglycemia
MBX生物科學公司宣佈，MBX 1416的1期單劑量和多劑量遞增試驗中最後一名受試者的最後一次訪視已完成，該藥物是公司正在開發用於治療減重手術後低血糖的長效胰高血糖素樣肽1受體拮抗劑。
MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of the last subject's last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the Company's long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist in development for the treatment of post-bariatric hypoglycemia (PBH).
MBX生物科學公司（納斯達克：MBX）是一家專注於發現和開發新型精確肽療法以治療內分泌和代謝疾病的臨床階段生物製藥公司，今天宣佈其MBX 1416的1期單劑量和多劑量遞增試驗中最後一名受試者的最後一次訪視已完成，該藥物是公司正在開發用於治療減重手術後低血糖（PBH）的長效胰高血糖素樣肽1（GLP-1）受體拮抗劑。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間